Aortic stenosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 0
• PCSK9 3
• TTR 1
• GLP-1 0
• APOE 0
• NRF2 0
• AMPK 0
• EGFR 0
• ERK 0
• MAPK 0
• PI3K 0
• STAT3 0
• ACE2 0
• AKT 0
• BCL-2 0
• BRAF 0
• CD40 0
• CXCR4 0
• DPP-4 0
• IL-6 0
• mTOR 0
• PPAR 0
• STING 0
• TNF 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · R01

  Risk Prediction for aortic stenosis and the impact of statin therapy among adults >75 years old in the PREVENTABLE trial

  Johns Hopkins University· Baltimore, United States· US$632,235 awarded in fiscal year 2026· until May 2031

• NIH NHLBI · R01

  The Cellular and Molecular Role ofGATA4 in Bicuspid Aortic Valve Disease

  University of Arizona· Tucson, United States· US$726,242 awarded in fiscal year 2026· until May 2030

• NIH NHLBI · F32

  Characterizing Neoaortic Valve Biomechanics in the Ross Procedure

  Stanford University· Stanford, United States· US$81,580 awarded in fiscal year 2026· until Aug 2028

• NIH NHLBI · K08

  Multi-omic evaluation of atherogenic and non-atherogenic mechanisms and risk in calcific aortic valve disease

  Brigham and Women's Hospital· Boston, United States· US$167,400 awarded in fiscal year 2026· until Jun 2031

• NIH NHLBI · R01

  Optimized development of novel leaflet biomaterials for replacement heart valves

  University of Texas at Austin· Austin, United States· US$1,296,842 awarded in fiscal year 2026· until May 2029

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  EuroHeartPath: Leading Innovation in Cardiovascular Pathways for Improved Patient Outcomes

  Universitair Medisch Centrum Utrecht· Utrecht, Netherlands· EU contribution €14,979,063· until Jan 2030· 10 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosis (CHIP-AVS)

  Johann Wolfgang Goethe-Universitaet Frankfurt Am Main· Frankfurt Am Main, Germany· EU contribution €2,225,906· until Oct 2027

7 of 38 running projects, newest first. Listed amounts together: US$18.8m + €17.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 19
• Gene Expression Profiling 20
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 5
• Proteomics 10
• Metabolomics 4
• Immunohistochemistry 3
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 47
• Machine Learning 24
• Deep Learning 17
• Cohort Studies 40
• Genome-Wide Association Study 18

• Unraveling the cellular characteristics of cardiomyopathy with rare variant-driven gene signatures using multi-omics analysis.

  Sci Rep, Dec 2025

• Correlation of Differential Gene Expression and Clinical Variations in Hypertrophic Cardiomyopathy via Whole Genome Sequencing.

  Biotechnol Appl Biochem, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.